Featured Research

from universities, journals, and other organizations

Potential novel treatment for influenza discovered: Scientists pursue new therapies as deadly H7N9 flu spreads in China

Date:
May 1, 2013
Source:
University of Maryland Medical Center
Summary:
An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to new research. The scientists found that a drug called Eritoran can protect mice from death after they have been infected with a lethal dose of influenza virus.

New findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China -- 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.
Credit: chuugo / Fotolia

An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1. The scientists found that a drug called Eritoran can protect mice from death after they have been infected with a lethal dose of influenza virus. The potential value of this drug as single therapy or in combination with antivirals is further supported by previous research that found that it is safe for use in humans.

The findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China -- 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.

Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4). Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality. In their new study, they extend these findings by showing that Eritoran -- a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis -- improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus. Existing antiviral medications must be administered within two days of infection to be optimally effective.

Annual influenza epidemics are estimated to result in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths yearly worldwide. The virus is continually evolving and new variants give rise to seasonal outbreaks. Increasing resistance to existing antiviral therapies and the short time-frame in which these agents are effective highlight the critical need for new treatments, such as Eritoran. This study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"Currently, vaccines and antiviral medications are the two main approaches to preventing influenza," says Dr. Vogel. "Problems associated vaccine development may limit efficacy and/or vaccine availability. In addition, people suffering from influenza may not go to the doctor or to the emergency room in time for the antivirals to be effective. Also, as the flu adapts to resist existing treatments, we are in search of new therapies to save lives and prevent severe illness. Our research seems to show that Eritoran could provide doctors with a new tool in their flu-fighting toolbox, as well as several more days to treat the sickest of patients successfully. More basic research is needed, but we are hopeful that this medication could one day change the way that we treat severe influenza and possibly other pathogens that cause disease by a similar mechanism."


Story Source:

The above story is based on materials provided by University of Maryland Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kari Ann Shirey, Wendy Lai, Alison J. Scott, Michael Lipsky, Pragnesh Mistry, Lioubov M. Pletneva, Christopher L. Karp, Jaclyn McAlees, Theresa L. Gioannini, Jerrold Weiss, Wilbur H. Chen, Robert K. Ernst, Daniel P. Rossignol, Fabian Gusovsky, Jorge C. G. Blanco, Stefanie N. Vogel. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature, 2013; DOI: 10.1038/nature12118

Cite This Page:

University of Maryland Medical Center. "Potential novel treatment for influenza discovered: Scientists pursue new therapies as deadly H7N9 flu spreads in China." ScienceDaily. ScienceDaily, 1 May 2013. <www.sciencedaily.com/releases/2013/05/130501154440.htm>.
University of Maryland Medical Center. (2013, May 1). Potential novel treatment for influenza discovered: Scientists pursue new therapies as deadly H7N9 flu spreads in China. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2013/05/130501154440.htm
University of Maryland Medical Center. "Potential novel treatment for influenza discovered: Scientists pursue new therapies as deadly H7N9 flu spreads in China." ScienceDaily. www.sciencedaily.com/releases/2013/05/130501154440.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins